Trial Profile

DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig Versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 30 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rilvegostomig (Primary) ; Trastuzumab-deruxtecan (Primary) ; Cisplatin; Durvalumab; Gemcitabine
Indications Biliary cancer
Focus Adverse reactions; Therapeutic Use
Acronyms DESTINY-BTC01
Sponsors AstraZeneca

02 Dec 2024 According to Daiichi Sankyo Company Media Release, data from DESTINY-PanTumor02 part 2, will be presented in a poster session on December 7, 2024, 5:50 - 6:45 pm at ESMO Asia 2024.
19 Sep 2024 Planned End Date changed from 30 Mar 2029 to 16 May 2029.
19 Sep 2024 Planned primary completion date changed from 26 Apr 2028 to 12 Jun 2028.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com